|
Getting your Trinity Audio player ready...
|
GPCR Therapeutics, a venture-backed, clinical stage international biopharmaceutical company, announced last week that it would be relocating its incubator space from San Carlos to Redwood City.
The company, which specializes in drug discovery by targeting G Protein Coupled Receptors (GPCR) pairs, is excited to be moving to the new location, according to the company’s founder and CEO, Dr. Dong Seung Seen.
“We are delighted to be growing in one of the world’s biggest and best biotech clusters, as neighbors to pharma companies including AbbVie and Bristol Myers Squibb, and many other innovation-driven biotech companies,” Seen said.
The Redwood City-based location will be dedicating its time to its research and development efforts, as well as accommodating capabilities in cell culture, protein engineering, computational chemistry, and high-throughput screening, according to a GPCR Therapeutics press release.
With the company’s innovative approach, it aims to develop life-changing treatments for cancer and other diseases.
As the company expands and recruits more people to its scientific teams, GPCR Therapeutics is looking to scale its R&D and is hopeful that it can begin its first human clinical trials sometime in the future.
“We will be proud to launch our first human clinical trials, resulting from outstanding work done over many years by our exceptional teams in South Korea and the U.S.A.,” Seen said.
The company’s new U.S. location in Redwood City will be opening on Sept. 15. There will be a ribbon-cutting ceremony at 11 a.m. that day to commemorate the opening.
